-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Camp4 Therapeutics, Raises Price Target to $9

Benzinga·04/02/2026 14:50:05
Listen to the news
Leerink Partners analyst Mani Foroohar maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform and raises the price target from $8 to $9.